Diffuse midline glioma

Diffuse Midline Glioma

MRI scan showing a diffuse midline glioma in the brainstem.

Diffuse midline glioma is a type of brain tumor that occurs primarily in children, although it can also be found in adults. These tumors are characterized by their location in the midline structures of the brain, such as the thalamus, brainstem, and spinal cord. They are highly aggressive and are classified as World Health Organization (WHO) grade IV tumors.

Pathophysiology

Diffuse midline gliomas are infiltrative tumors that spread along the white matter tracts of the brain. They are often associated with mutations in the H3 K27M gene, which is a hallmark of this tumor type. These mutations lead to changes in the chromatin structure, affecting gene expression and promoting tumor growth.

Diagram showing common mutations in diffuse intrinsic pontine glioma.

Clinical Presentation

Patients with diffuse midline glioma typically present with symptoms related to the location of the tumor. For example, tumors in the brainstem may cause cranial nerve deficits, difficulty swallowing, and problems with balance and coordination. Tumors in the thalamus can lead to sensory and motor deficits, while spinal cord involvement may cause weakness and sensory changes in the limbs.

Diagnosis

Diagnosis of diffuse midline glioma is primarily based on magnetic resonance imaging (MRI) findings. The tumors appear as poorly defined, infiltrative masses that enhance with contrast. A biopsy may be performed to confirm the diagnosis and identify specific genetic mutations.

Treatment

Illustration of drug delivery methods for treating diffuse intrinsic pontine glioma.

Treatment options for diffuse midline glioma are limited. The standard approach is radiation therapy, which can provide temporary relief of symptoms and slow tumor progression. Chemotherapy has not been shown to be effective in most cases. Research is ongoing to find new treatments, including targeted therapies and immunotherapy.

Prognosis

The prognosis for patients with diffuse midline glioma is poor, with a median survival of less than one year. The aggressive nature of the tumor and its location in critical areas of the brain make it difficult to treat effectively.

Research Directions

Ongoing research is focused on understanding the molecular mechanisms underlying diffuse midline glioma and developing new therapeutic strategies. Studies are exploring the use of targeted therapies that specifically inhibit the pathways activated by the H3 K27M mutation.

Graphical abstract of a molecular meta-analysis of pediatric high-grade gliomas.

Related Pages

• Glioblastoma
• Pediatric brain tumor
• Radiation therapy
• Targeted therapy